Pyrimidine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer have been disclosed in a recent Asieris Pharmaceuticals Co. Ltd. patent.
Exelixis Inc. has synthesized fused pyrazole derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Work at Tango Therapeutics Inc. has led to the identification of new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Laekna Therapeutics Shanghai Co. Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Guangdong Newopp Biopharmaceuticals Co. Ltd. has identified macrocyclic derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Impact Therapeutics (Shanghai) Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
